Clonal hematopoiesis of indeterminate potential (CHIP), increasingly recognized as a driver of cardiovascular disease, is now emerging as a clinically relevant factor in oncology treatment safety. A new study published in JAMA Oncology (Park et al., 2026) provides compelling evidence that CHIP is associated with a significantly increased risk of Trastuzumab-Related Cardiotoxicity in patients with breast cancer.
These findings introduce an additional layer of complexity to cardio-oncology, suggesting that underlying hematopoietic mutations may influence how patients tolerate targeted cancer therapies.
Read About Trastuzumab Deruxtecan Side Effects on OncoDaily
Why This Question Matters in Modern Breast Cancer Care
Trastuzumab has fundamentally transformed outcomes in HER2-positive breast cancer, significantly improving survival across early and metastatic settings. However, cardiotoxicity, particularly left ventricular dysfunction and heart failure, remains a well-established risk associated with its use.
As survivorship improves and treatment durations extend, identifying patients at higher risk of cardiotoxicity has become increasingly important. Traditional risk stratification relies on clinical factors such as age, prior anthracycline exposure, and baseline cardiovascular disease. However, these factors do not fully explain variability in cardiac outcomes.
CHIP, defined by the presence of somatic mutations in hematopoietic stem cells without overt hematologic malignancy, has been linked to inflammation and increased cardiovascular risk. This study explores whether CHIP may also modulate susceptibility to therapy-related cardiac injury.
Study Design Across Human Cohorts and Experimental Models
The investigators conducted a multi-layered analysis combining population-level data, institutional clinical cohorts, and mechanistic animal models.
The primary analysis included 15,729 patients with breast cancer from the UK Biobank, with a mean age of 58.8 years. A second, independent validation cohort consisted of 454 patients treated with trastuzumab at Seoul National University Hospital, with a mean age of 52 years.
The main outcomes were incident heart failure in the population-based cohort and clinically defined trastuzumab-related cardiotoxicity in the institutional cohort, using established criteria from the European Society of Cardiology, the Canadian Trastuzumab Working Group, and the Cardiac Review and Evaluation Committee.
To explore biological mechanisms, the study also incorporated a mouse model of Tet2-deficient clonal hematopoiesis exposed to trastuzumab.
CHIP Is Associated With Increased Cardiotoxic Risk
Across both clinical cohorts, the presence of CHIP was consistently associated with higher rates of cardiotoxic effects.
In the Seoul cohort, the 2-year cumulative incidence of cardiotoxicity was markedly higher in patients with CHIP, reaching:
- 15.7% versus 5.0% using ESC criteria
- 19.9% versus 10.8% using Canadian criteria
- 20.9% versus 11.3% using CREC criteria
These differences were statistically significant across all definitions.
In multivariable analysis, CHIP positivity was associated with a nearly twofold increase in risk of cardiotoxicity (adjusted subdistribution hazard ratio 1.91; 95% CI 1.32–2.76), independent of traditional cardiovascular risk factors and prior anthracycline exposure.
Importantly, the study also observed a dose-response relationship, with larger CHIP clones associated with higher risk, reinforcing the biological plausibility of the findings.
Mechanistic Insight From Experimental Models
To move beyond association, the investigators explored causality using a Tet2-deficient mouse model, a well-established representation of CHIP.
Following trastuzumab exposure, these mice demonstrated a significant reduction in left ventricular ejection fraction, with an average decrease of 4.2%. In contrast, control groups without Tet2 deficiency did not show meaningful cardiac dysfunction.
This finding supports a mechanistic link between CHIP and increased susceptibility to cardiotoxic injury, potentially mediated through inflammatory pathways and altered immune signaling.
Interpreting the Findings in Clinical Context
These results suggest that CHIP may serve as an independent and clinically meaningful biomarker for identifying patients at increased risk of trastuzumab-related cardiotoxicity.
While routine screening for CHIP is not currently part of standard oncology practice, the growing accessibility of genomic testing raises the possibility that CHIP status could be incorporated into risk stratification models in the future.
For clinicians, the findings highlight the importance of individualized cardiac monitoring strategies. Patients with known CHIP, or those identified through future screening approaches, may benefit from closer surveillance, earlier intervention, or modified treatment strategies.
Read About Breast Cancer on OncoDaily
Limitations and Future Directions
Despite its strengths, including large-scale population data and mechanistic validation, the study has limitations.
The observational design limits causal inference in human cohorts, and CHIP detection thresholds and definitions may vary across studies. Additionally, the clinical implementation of CHIP testing remains uncertain, particularly in terms of cost-effectiveness and integration into routine care pathways.
Prospective studies are needed to determine whether CHIP-guided strategies can reduce cardiotoxic events without compromising oncologic outcomes.
The Bottom Line
This study identifies clonal hematopoiesis as a significant risk factor for trastuzumab-related cardiotoxicity, supported by both clinical and experimental evidence.
As cardio-oncology continues to evolve, these findings reinforce a broader shift toward integrating genomic and biological factors into treatment decision-making, not only to improve efficacy, but also to minimize harm.